Skip to main content

Advertisement

SpringerLink
Log in

Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer

  • Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The importance of cyclin-dependent kinase inhibitors (CDKI) in benign and malignant urological diseases is a subject of intense ongoing investigation. The goal of the current study was to analyze the expression of p27(Kip1) CDKI in benign and malignant renal cells and assess their possible association with different clinical parameters. Expression of p27(Kip1) was evaluated and compared in 24 normal human kidneys and in 52 renal cell carcinoma (RCC) tissue samples. Intensity of the expression was compared between the groups and association was analyzed with cancer clinical parameters. The expression of the marker was significantly higher in normal than in RCC samples (P = 0.0045). Intensity of p27(Kip1) expression in RCC was negatively correlated with tumor size (Rho = −0.438, P = 0.0051) and associated with pathological stage and grade (P = 0.0488 and < 0.0001, respectively). The patients with symptomatic disease had significantly less marker expression than incidentally discovered tumors (P = 0.0301). Loss of p27(Kip1) expression, pathological stage, grade and tumor size were the risk-factors for disease recurrence (P = 0.0072, 0.0011, 0.0467 and < 0.0001, respectively) and patient survival (P = 0.0021, 0.0106, 0.0151 and 0.0021, respectively). With Cox multivariate analysis loss of p27(Kip1) expression (hazard ratio 9.3, P = 0.002) and tumor size (hazard ratio 5.9, P = 0.015) were the predictors of cancer-specific survival. Expression of p27(Kip1) is significantly decreased in RCC as compared with normal kidney tissue. Intensity of the expression is associated with clinical parameters: tumor size, stage, grade and disease presentation. Loss of p27(Kip1) expression is a risk-factor for disease recurrence and the strongest predictor of cancer-specific survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Tiwari RC, Murray T et al (2004) Cancer statistics. CA Cancer J Clin 54:8–29

    Article  PubMed  Google Scholar 

  2. Lam JS, Shvarts O, Leppert JT et al (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173:1853–1862

    Article  PubMed  Google Scholar 

  3. Kontak JA, Campbell SC (2003) Prognostic factors in renal cell carcinoma. Urol Clin North Am 30:467–481

    Article  PubMed  Google Scholar 

  4. Oosterwijk E (2005) Tumor markers for renal cell carcinoma. J Urol 173:2150–2155

    Article  Google Scholar 

  5. Lam JS, Leppert JT, Figlin RA et al (2005) Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 66(S5):1–9

    Article  PubMed  Google Scholar 

  6. de Kernion JB (2005) Reexamination of current staging for renal cell carcinoma. J Urol 173:680

    Article  Google Scholar 

  7. Shvarts O, Lam JS, Kim HL et al (2005) Staging of renal cell carcinoma: current concepts. BJU Int 95:8–13

    Article  PubMed  Google Scholar 

  8. Kawamata N, Morosetti R, Miller CW et al (1995) Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res 55:2266–2269

    PubMed  CAS  Google Scholar 

  9. Gizard F, Robillard R, Gervois P et al (2005) Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. FEBS Lett 579:5535–5541

    Article  PubMed  CAS  Google Scholar 

  10. Galizia G, Ferraraccio F, Lieto E et al (2004) Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum 47:1904–1914

    Article  PubMed  Google Scholar 

  11. Singhal S, Vachani A, Antin-Ozerkis D et al (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11:3974–3986

    Article  PubMed  CAS  Google Scholar 

  12. Revelos K, Petraki C, Gregorakis A et al (2005) p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo 19:911–920

    PubMed  CAS  Google Scholar 

  13. Dreher T, Zentgraf H, Abel U et al (2004) Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies. Virchows Arch 444:509–517

    Article  PubMed  Google Scholar 

  14. Langner C, von Wasielewski R, Ratschek M et al (2004) Expression of p27 and its ubiquitin ligase subunit Skp2 in upper urinary tract transitional cell carcinoma. Urology 4:611–616

    Article  Google Scholar 

  15. Strauss M, Lukas J, Bartek J et al (1995) Unrestricted cell cycling and cancer. Nat Med 1:1245–1246

    Article  PubMed  CAS  Google Scholar 

  16. Sherr CJ (1996) Cancer cell cycles. Science 274:1672–1677

    Article  PubMed  CAS  Google Scholar 

  17. Haitel A, Wiener HG, Neudert B et al (2001) Expression of the cell cycle proteins p21, p27 and pRb in clear renal cell carcinoma and their prognostic significance. Urology 58:477–481

    Article  PubMed  CAS  Google Scholar 

  18. Migita T, Oda Y, Naito S et al (2002) Low expression of p27 KIP1 is associated with tumor size and poor prognosis in patients with Renal Cell Carcinoma. Cancer 94:973–979

    Article  PubMed  CAS  Google Scholar 

  19. Hedberg Y, Davoodia E, Ljunberg B et al (2002) Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer 20:601–607

    Article  CAS  Google Scholar 

  20. Hedberg Y, Ljungberg B, Roos G et al (2003) Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 88:1417–1422

    Article  PubMed  CAS  Google Scholar 

  21. Langner C, von Wasielewski R, Ratschek M et al (2004) Biological significance of p27 and Skp2 expression in renal cell carcinoma. A systematic analysis of primary and metastatic tumour tissues using a tissue microarray technique. Virchows Arch 445:631–636

    Article  PubMed  CAS  Google Scholar 

  22. Langner C, Rehak P, Ratschek M et al (2005) The pT1a and pT1b category subdivision in renal cell carcinoma: is it reflected by differences in tumour biology? BJU Int 95:310–314

    Article  PubMed  Google Scholar 

  23. Guinan P, Sobin LH, Algaba F et al (1997) TNM staging of renal cell carcinoma: Workgroup No. 3-Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80:992–993

    Article  PubMed  CAS  Google Scholar 

  24. Melk A, Scmidt BMW, Takeuchi O et al (2004) Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidneys. Kidney Int 65:510–520

    Article  PubMed  CAS  Google Scholar 

  25. von Schnakenburg C, Strehlau J, Ehrich J, Melk A (2002) Quantitative gene expression of TGF-beta1, IL-10, TNF-alpha and Fas Ligand in renal cortex and medulla. Nephrol Dial Transplant 17:573–579

    Article  Google Scholar 

Download references

Acknowledgment

The study was supported by grants from Roche and Pfizer Georgia.

Author information

Authors and Affiliations

  1. Departments of Adult Urology, National Centre of Urology, Tsinandali st. 9, 0144, Tbilisi, Georgia

    Ambrosi Pertia, David Nikoleishvili, Laurent Managadze & Archil Chkhotua

  2. Departments of Pathology, National Centre of Urology, Tbilisi, Georgia

    Omar Trsintsadze

  3. Department of Laboratory Diagnosis, Tbilisi State Medical Academy, Tbilisi, Georgia

    Nino Gogokhia

Authors
  1. Ambrosi Pertia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Nikoleishvili
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Omar Trsintsadze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nino Gogokhia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laurent Managadze
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Archil Chkhotua
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Archil Chkhotua.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pertia, A., Nikoleishvili, D., Trsintsadze, O. et al. Loss of p27(Kip1) CDKI is a predictor of poor recurrence-free and cancer-specific survival in patients with renal cancer. Int Urol Nephrol 39, 381–387 (2007). https://doi.org/10.1007/s11255-006-9077-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-006-9077-6

Keywords

Search

Navigation